Drug Discovery Outsourcing Market Forecast 2016-2026

LONDON, September 26, 2016 /PRNewswire/ --

Chemistry Services, Biology Services, Lead Optimisation, Lead Identification and Screening

Where is the drug discovery outsourcing market heading? Visiongain's new report gives you revenue predictions for the drug discovery outsourcing market and its submarkets from 2016 to 2026, helping you stay ahead.

Visiongain's new 232-page report provides revenue forecasts to 2026 for the global drug discovery outsourcing market, four leading submarkets and 13 leading national markets. The report profiles 14 leading CROs providing drug discovery outsourcing, and includes revenue forecasts and analysis to 2026 for 6 of those companies. It also includes 3 interview transcripts with industry experts regarding the current developments and the drivers of growth in the drug discovery outsourcing market.

Besides revenue forecast to 2026, this report provides market shares, business outlooks, qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial partnerships.

See revenue forecasts for leading drug discovery outsourcing sectors
Along with prediction of overall world market value to 2026, our report shows you revenue forecasting for the four services sectors at world level:
• Chemistry services market forecast 2016-2026
• Biology services market forecast 2016-2026
• Lead optimisation market forecast 2016-2026
• Lead identification and screening market forecast 2016-2026

The analysis helps you identify market potential with individual revenue forecasts, annual growth rates and CAGRs and market shares.

Discover prospects of the leading national markets for the drug discovery outsourcing
The drug discovery outsourcing market is becoming increasingly global as companies look to lower costs by off-shoring their work to CROs based in emerging economies.

You will discover individual revenue forecasts, annual growth rates, CAGRs, and market shares to 2026, as well as written supporting analyses for each of the 13 leading national markets and the rest of the world (RoW):
• US
• Japan
• Germany
• France
• UK
• Italy
• Spain
• China
• Brazil
• Russia
• India
• South Korea
• Mexico
• Rest of the World

Demand for CROs based in emerging markets will be a major driver of growth in this market.

Leading companies and potential for market growth
Our new study predicts the world market for drug discovery outsourcing will reach $19.2bn in 2016. There is the increasing trend for pharmaceutical and biotech companies to form partnerships and alliances with CROs during the early drug discovery phase.

Our research profiles leading companies, assessing their financial performance and products. You will see which organisations hold the greatest potential and what services each offer. See the profiles of 14 leading companies:

• Albany Molecular Research (AMRI)
• Aptuit
• Charles River Laboratories
• Covance
• Cyprotex
• Domainex
• Evotec
• GenScript
• Pharmaceutical Product Development (PPD)
• Quintiles
• Selcia
• Viva Biotech
• WIL Research Laboratories
• WuXi AppTec

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

To request a report overview of this report please emails Sara Peerun at sara.peerun@visiongainglobal.com or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1728/Drug-Discovery-Outsourcing-Market-Forecast-2016-2026

Organisations and Companies Mentioned 

AbbVie

Actavis

Acurian

Advion Bioanalytical Labs

Albany Molecular Research (AMRI)

Apredica

Aptuit

Argenta

Ark Therapeutics

Astex

AstraZeneca

Auspherix

Bayer

Behrman Capital

Beijing Genomics Institute

BioCity

Bio Pontis Alliance

BioDuro

BioFocus

Boehringer Ingelheim

Bristol Myers Squibb

Cantab

CaprionProteomics

Carlyle Group

Catalent

ChanTest

Charles River Laboratories

CHDI

CHDI Foundation

CONBA

Covance

Cyprotex

Domainex

Elan

Eli Lilly

Evotec

Exquiron Biotech

Forma Therapeutics

Galapagos

Genentech

GenScript

GlaxoSmithKline

Great Lakes Chemical Corp

Harvard

Horizon

Hypha Discovery

IMI

Janssen Pharmaceutical

JingXin

Johnson & Johnson

Kellogg Company

Keucept

Knopp Biosciences

Laboratory Corporation of America

Laurus Labs

MedImmune

Merck

Midwest Bio Research

Milner Therapeutics Institute and Consortium

MIT

Next CODE Health

Parexel

Pharmaceutical Product Development (PPD)

PhRMA (Pharmaceutical Research and Manufacturers of America)

National Institutes of Health

Ono

Proteros Biostructures

Quintile

Roche

Sanofi

Selcia

Shionogi

Siena Biotech

The Babraham Institute

The Sanger Institute

UCB

University of Cambridge

University of Edinburgh

Viva Biotech

Vivo Path

WIL Research Laboratories

WuXi AppTec

WuXi PharmaTech